Quercetin: Anti-Inflammatory, Antiviral, Quercetin & Cardiovascular Health — Evidence Review
⚡ 60-Second Summary
Quercetin (3,3′,4′,5,7-pentahydroxyflavone) is one of the most abundant dietary flavonoids, found in onions, apples, capers, kale, and many other plants. It is a broad-spectrum flavonoid with anti-inflammatory, antioxidant, antiviral, antihistamine, and emerging senolytic properties. However, plain quercetin has very poor oral bioavailability (~1%) — enhanced delivery forms (phytosome, nanoparticle) are needed for reliable therapeutic plasma levels.
Best-evidenced uses: Upper respiratory infection prevention and reduction in athletes (multiple RCTs); anti-inflammatory and antioxidant effects; blood pressure reduction (meta-analyses show modest effect); antiviral activity (inhibits viral entry and replication across multiple viruses); senolytic activity (first human dasatinib+quercetin senolytic trial showed senescent cell clearance); cardiovascular markers. The breadth of potential applications is notable, though individual effect sizes are often modest.
Practical note: Quercetin bioavailability is the defining challenge. Plain quercetin (aglycone) has ~1% oral bioavailability. Quercetin phytosome (Quercefit — 50 mg quercetin: 50 mg phosphatidylcholine, 20× better absorption) and quercetin glycosides (isoquercetin — much better absorption than aglycone) are the preferred forms. The quercetin that reaches plasma is what produces systemic effects.
What is Quercetin?
Quercetin's anti-inflammatory mechanism centers on inhibiting NF-κB (reduces inflammatory gene expression), MAPK pathways (reduces AP-1-driven inflammation), NLRP3 inflammasome (reduces IL-1β and IL-18), and releasing histamine from mast cells (antihistamine effect). Its antiviral mechanism involves inhibiting viral RNA polymerase, helicase activity, and viral protease enzymes — demonstrated against rhinovirus, influenza, SARS-CoV-2, and many other viruses in vitro. Senolytic activity involves inhibiting PI3K/Akt and BCL-2 pro-survival pathways in senescent cells.
Quercetin has been studied since the 1970s and has one of the largest flavonoid research databases. Interest in quercetin for athletes increased after a 2007 meta-analysis (Nieman et al.) showing URI prevention. Antiviral interest spiked during COVID-19 research (2020–2021). The senolytic research program (dasatinib + quercetin, Mayo Clinic) began in 2015 and has produced the first human senolytic clinical trials. Quercefit (phytosomal quercetin) was developed to address the bioavailability problem.
Evidence-based benefits
1. Upper respiratory infection prevention
Meta-analysis (Somerville 2016): quercetin (500–1,000 mg/day) reduces URI incidence by ~31% and duration by 36% in athletes and highly stressed individuals. Effect is smallest in people under moderate exercise stress.
2. Anti-inflammatory and antioxidant
Multiple RCTs show quercetin reduces CRP, IL-6, TNF-alpha and increases antioxidant capacity. Blood pressure meta-analyses show ~3–4 mmHg systolic reduction at 500+ mg/day.
3. Senolytic activity (with dasatinib)
Mayo Clinic trials show dasatinib (cancer drug) + quercetin clears senescent cells in human fat tissue and kidney, reducing senescent cell markers. This is the first human senolytic evidence — quercetin's role is specifically as a senolytic (not antioxidant) at these doses.
4. Antiviral activity
In vitro and some animal studies show quercetin inhibits replication of rhinovirus, influenza, coronavirus, and other pathogens. Limited human clinical evidence for specific antiviral indications, but mechanistic basis is strong.
Supplement forms compared
| Form | Typical dose / Bioavailability | Best for | Notes |
|---|---|---|---|
| Quercetin phytosome (Quercefit — 500 mg = ~20× better absorption) | 250–500 mg/day | All systemic uses — best bioavailability | Most bioavailable commercial form. 500 mg Quercefit ≈ 10,000 mg plain quercetin systemically. |
| Isoquercetin (quercetin-3-glucoside) | 100–500 mg/day | Anti-inflammatory, cardiovascular — better absorption than aglycone | Glycoside form absorbed better; available in some products and foods. |
| Plain quercetin (aglycone) | 1,000–2,000 mg/day | Lower bioavailability — requires higher dose | Must use high doses to compensate for ~1% bioavailability. Less predictable. |
| Quercetin + bromelain | 500 mg quercetin + 400 mg bromelain/day | Anti-inflammatory, URI prevention | Bromelain may enhance quercetin absorption; combination used in clinical trials. |
How much should you take?
- URI prevention: 500–1,000 mg/day quercetin (preferably phytosome or isoquercetin form)
- Anti-inflammatory/cardiovascular: 500–1,000 mg/day
- Senolytic protocol (with dasatinib): not appropriate without physician supervision
Plain quercetin is very safe at up to 1,000 mg/day in clinical trials. Enhanced-bioavailability forms are also well-tolerated. The main interactions are theoretical: quercetin inhibits CYP3A4 and CYP2C9 at high concentrations, potentially affecting drug metabolism. Clinical significance at typical supplement doses is uncertain but warrants monitoring with polypharmacy.
Safety and side effects
Common side effects
- Mild GI upset (uncommon at typical doses)
- Possible headache
- CYP3A4, CYP2C9 inhibition at high doses — drug interaction potential
- Rare: kidney stones risk at very high doses (in animals); limited human data
Serious risks
Quercetin is well-tolerated with an excellent clinical safety profile. The CYP enzyme inhibition at high doses is the main drug interaction concern. People on multiple medications should confirm safety with their pharmacist.
Drug and nutrient interactions
- Warfarin — CYP2C9 inhibition may increase warfarin levels; monitor INR
- Immunosuppressants (cyclosporine, tacrolimus) — CYP3A4 inhibition at high doses may increase drug levels; monitor
- Antibiotics (ciprofloxacin) — quercetin may reduce absorption if taken simultaneously; take separately
- Chemotherapy — complex interactions; discuss with oncologist
Check our free interaction checker for additional combinations.
Who might benefit — and who should use caution
| Most likely to benefit | Use with caution or seek guidance |
|---|---|
| Athletes and highly active individuals seeking URI prevention during intense training | People on cyclosporine or tacrolimus — possible CYP3A4 drug level increase |
| Adults with chronic inflammation, high CRP, or cardiovascular risk factors | People on warfarin — monitor INR with high-dose quercetin |
| Those interested in senolytic supplements alongside fisetin or other longevity compounds | Pregnant or breastfeeding women — safety not established |
| Individuals with seasonal allergies using quercetin's antihistamine properties |
Frequently asked questions
Does quercetin really prevent colds?
Multiple meta-analyses show quercetin at 500–1,000 mg/day reduces URI incidence by ~30% in athletes and stressed individuals. The effect is most consistent in people under high physical or mental stress. The mechanism involves antiviral activity (inhibiting viral replication) and immune modulation. It is not as effective as vaccination for influenza prevention, but is a meaningful dietary approach to URI reduction.
Is quercetin good for allergies?
Quercetin inhibits histamine release from mast cells — giving it antihistamine properties distinct from H1-receptor blockers. Multiple in vitro and some clinical studies show reduced allergic reactions. The effect is more relevant as a preventive (long-term supplementation before allergy season) than as an acute antihistamine. It works best combined with vitamin C and bromelain in some allergy protocols.
What is the bioavailability problem with quercetin?
Plain quercetin (aglycone) has approximately 1% oral bioavailability — almost none reaches the bloodstream. Multiple barriers explain this: poor gut dissolution (quercetin is poorly water-soluble), rapid conjugation in the gut wall and liver, and rapid elimination. Phytosomal quercetin (Quercefit) uses phosphatidylcholine complexation to dramatically improve absorption — approximately 20× better than plain quercetin in pharmacokinetic studies.
How does quercetin work as a senolytic?
In the context of the Mayo Clinic dasatinib + quercetin (D+Q) senolytic protocol, quercetin inhibits BCL-2, BCL-XL, and PI3K/Akt pro-survival pathways that senescent cells depend on to avoid apoptosis (programmed cell death). This selectively kills senescent cells. Note: quercetin's senolytic doses and mechanism differ from its antioxidant/anti-inflammatory role. The D+Q protocol requires a cancer drug (dasatinib) and physician oversight — not appropriate for self-medication.
Should I combine quercetin with zinc?
The quercetin + zinc combination became popular during COVID-19 because in vitro data shows quercetin acts as a zinc ionophore — facilitating zinc entry into cells, where zinc inhibits viral RNA polymerase. This mechanism is biologically plausible. However, clinical evidence for this specific combination is limited. Both quercetin and zinc independently have some evidence for URI prevention, and the combination is generally safe at moderate doses.
Related ingredients
Fisetin
Related senolytic flavonoid with stronger comparative senolytic evidence.
Quercetin Phytosome (Quercefit)
The bioavailability-enhanced form of quercetin — same molecule, dramatically better absorption.
Vitamin C
Often combined with quercetin for synergistic antioxidant and URI prevention effects.
Disclaimer: This information is for educational purposes only and should not replace medical advice. Always consult a qualified healthcare provider before starting any supplement, especially if you have a medical condition, are pregnant, or take prescription medications. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.